000			01617 a2200445 4500
005			20250513120327.0
264		0	_c19970529
008			199705s 0 0 eng d
022			_a0006-3223
024	7		_a10.1016/0006-3223(95)00098-4 _2doi
040			_aNLM _beng _cNLM
100	1		_aMiller, C
245	0	0	_aCSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin). _h[electronic resource]
260			_bBiological psychiatry _cJun 1996
300			_a911-8 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aBiogenic Amines _xcerebrospinal fluid
650	0	4	_aChromatography, High Pressure Liquid
650	0	4	_aChromogranin A
650	0	4	_aChromogranins _xcerebrospinal fluid
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aNeuropeptides _xcerebrospinal fluid
650	0	4	_aPsychiatric Status Rating Scales
650	0	4	_aRadioimmunoassay
650	0	4	_aSchizophrenia _xcerebrospinal fluid
650	0	4	_aSecretogranin II
650	0	4	_aSubstance P _xcerebrospinal fluid
700	1		_aKirchmair, R
700	1		_aTroger, J
700	1		_aSaria, A
700	1		_aFleischhacker, W W
700	1		_aFischer-Colbrie, R
700	1		_aBenzer, A
700	1		_aWinkler, H
773	0		_tBiological psychiatry _gvol. 39 _gno. 11 _gp. 911-8
856	4	0	_uhttps://doi.org/10.1016/0006-3223(95)00098-4 _zAvailable from publisher's website
999			_c9143412 _d9143412